Comerica Bank
APLS

Comerica Bank’s Apellis Pharmaceuticals APLS Stock Holding History

Comerica Bank’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$7.91K Sell
315
-51
-14% -$1.2K ﹤0.01% 3299
2025
Q3 		$8.28K Buy
366
+51
+16% +$1.19K ﹤0.01% 3291
2025
Q2 		$5.45K Buy
315
+53
+20% +$981 ﹤0.01% 3354
2025
Q1 		$5.73K Sell
262
-286
-52% -$7.9K ﹤0.01% 3300
2024
Q4 		$17.5K Sell
548
-1,261
-70% -$37.9K ﹤0.01% 3066
2024
Q3 		$52.2K Sell
1,809
-6,546
-78% -$242K ﹤0.01% 2787
2024
Q2 		$321K Buy
8,355
+192
+2% +$8.7K ﹤0.01% 2041
2024
Q1 		$480K Buy
8,163
+6,804
+501% +$434K ﹤0.01% 1888
2023
Q4 		$81.3K Sell
1,359
-94,820
-99% -$4.81M ﹤0.01% 2572
2023
Q3 		$3.66M Buy
+96,179
New +$4.22M 0.02% 771
2022
Q4 		$3.44M Buy
+66,230
New +$3.51M 0.03% 765

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Comerica Bank's APLS Position: Q4 2025 in Review

Comerica Bank reduced its Apellis Pharmaceuticals (APLS) stake by 14% in Q4 2025, selling an estimated $1.2K and leaving 315 shares worth $7.91K. The position accounts for ﹤0.01% of the portfolio, ranked #3299.

Comerica Bank first reported a position in APLS in Q4 2022 and has held it in 11 quarters since. The position peaked at $3.66M in Q3 2023. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • Comerica Bank held 315 shares of Apellis Pharmaceuticals worth $7.91K as of Q4 2025.
  • Comerica Bank sold 51 Apellis Pharmaceuticals shares in Q4 2025, an estimated $1.2K.
  • Apellis Pharmaceuticals made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3299 holding.
  • Comerica Bank first reported a position in Apellis Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
  • Comerica Bank's Apellis Pharmaceuticals position peaked at $3.66M in Q3 2023.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.